492 / 1498
•
Prognosis of r&r lymphoma still to be improved
•
DHAP or other reinduction followed by BEAM and autologous TX
standard in relapsed lymphoma
•
Intensification of chemotherapy not helpful (HDR2)
•
Anti-CD30 ADC BV effective and well tolerated; currently being
evaluated in combination with chemo and other drugs
•
Anti-PD1
´
s represent a new class of drugs showing very promising
activity in r/r lymphoma
•
Can new drugs replace radio- or chemotherapy in lymphoma?
Relapsed and refractory lymphoma
Summary